Search
Diabetes Paid Clinical Trials in Indiana
A listing of 25 Diabetes clinical trials in Indiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 25
The state of Indiana currently has 25 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study (Raleigh)
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 1
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Type 1 Diabetes
Featured Trial
Obese or Overweight Volunteers Needed for a Research Study
Recruiting
Enroll now in a research study for obese or overweight volunteers with heart disease, hypertension, T2DM, or high cholesterol. All study related assessments are provided at no cost. Compensation up to $125 per visit for qualified participants.
Conditions:
Obesity
Overweight
Overweight and Obesity
Diabetes Mellitus
Type 2
Featured Trial
Heart Failure Clinical Trial
Recruiting
You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: St. Vincents Hospital, Indianapolis, Indiana
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Denosumab for Type 1 Diabetes
Recruiting
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/24/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Type 1 Diabetes
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/24/2025
Locations: Indiana Medical Research Institute, Merrillville, Indiana
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: Indiana Nephrology, Fishers, Indiana
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Recruiting
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
07/22/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Type 1 Diabetes, Obesity
Innovative Automated Insulin Delivery System for Type 2 Diabetes
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: IU Health University Hospital, Indianapolis, Indiana
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Indiana University Health University Hospital, Indianapolis, Indiana
Conditions: Type 1 Diabetes, Obesity, Overweight
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Indiana Medical Research Institute, Indianapolis, Indiana +1 locations
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone.
Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Kidney and Hypertension Center of Wabash Valley LLC, Terre Haute, Indiana
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Bionic Pancreas in CFRD
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
07/10/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Cystic Fibrosis-related Diabetes
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Investigators Research Group, Brownsburg, Indiana
Conditions: Type 2 Diabetes
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin.
TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D.
The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: Riley Hospital for Children at IU Health- Site Number : 8400004, Indianapolis, Indiana
Conditions: Type 1 Diabetes